SEC Form 4														
FORM 4	UNITEI	UNITED STATES SECURITIES AND EXCHANGE COM Washington, D.C. 20549									OMB APPROVAL			
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).		AT OF CHANGES IN BENEFICIAL OWNE d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							OMB Number: 3235-026 Estimated average burden hours per response: 0					
1. Name and Address of Reporting Pers Wolin Jonathan S.		2. Issuer Name <b>and</b> Ticker or Trading Symbol Jaguar Health, Inc. [JAGX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify					
(Last)(First)C/O JAGUAR HEALTH, INC.200 PINE STREET, SUITE 400	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/28/2022							Chief of Staff, CCO & GC				
(Street) SAN FRANCISCO	94104		4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State)	(Zip)													
	Table I - No	n-Deriva	ative S	ecurities Acq	uired,	Disp	bosed of,	or Bene	eficially	Owned				
1. Title of Security (Instr. 3) 2. Trai Date (Mont			ction ay/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of			5. Amount of Securities Beneficially Owned Followi Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)			(11001.4)	
				curities Acqui IIs, warrants,						wned				

	(														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Restricted stock units <sup>(1)</sup>	(2)	03/28/2022 <sup>(3)</sup>		Α		196,018		(4)	(4)	Common Stock	196,018	\$0	196,018	D	

## Explanation of Responses:

1. Granted pursuant to the issuer's 2014 Stock Incentive Plan.

2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

3. The restricted stock unit grants were approved by the issuer's board of directors on March 28, 2022.

4. The restricted stock units vest in three equal annual installments beginning on May 17, 2023. Vested shares will be delivered to the reporting person on the vesting date provided in the grant notice.

## /s/ Jonathan S. Wolin

\*\* Signature of Reporting Person

03/30/2022

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.